Having both Systemic Mastocytosis (SM) and CMML-1 together is considered a more complex situation. When two blood conditions overlap like this, it can make treatment more challenging and may affect the overall outlook.
CMML-1 on its own means there are between 2–4% blast cells (immature cells) in the blood and 5–9% in the Show Full Answer
Having both Systemic Mastocytosis (SM) and CMML-1 together is considered a more complex situation. When two blood conditions overlap like this, it can make treatment more challenging and may affect the overall outlook.
CMML-1 on its own means there are between 2–4% blast cells (immature cells) in the blood and 5–9% in the bone marrow. This is a mid-range subtype, sitting between the earliest stage (CMML-0) and the more advanced stage (CMML-2). Prognosis with CMML depends on several personal factors, including:
- Age and overall health
- Blood cell counts
- Specific genetic mutations present
- The percentage of blasts in blood and bone marrow
- Whether the subtype is dysplastic (MD-CMML) or proliferative (MP-CMML)
Having an additional overlapping condition can influence treatment decisions and outcomes, so it's really important to have detailed conversations with a hematologist/oncologist who knows your full picture. They can give the most accurate and personalized guidance for managing both conditions together.
May 12
Join
Your Privacy Choices
